Tech Company Financing Transactions
Trace Biosciences Funding Round
Trace Biosciences secured a Series A venture capital round on 7/29/2026. Investors included Axogen.
Transaction Overview
Company Name
Announced On
7/29/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support its Phase II and III clinical trials toward a New Drug Application (NDA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1800 NW 167th Pl. 160
Beaverton, OR 97006
USA
Beaverton, OR 97006
USA
Phone
Website
Email Address
Overview
Trace Biosciences was founded by scientists driven by a simple belief: surgeons should be able to see the structures that matter most. For decades, nerves - essential to all aspects of daily life - have remained largely invisible in the operating room. We exist to change that. By making nerves visible in real time, we give surgeons clarity and are motivated to bring this groundbreaking technology to every OR.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Connor Barth
Chief Operating Officer
Scott Houston
Chief Scientific Officer
Summer Gibbs
Chief Technical Officer
Lei Wang
VP - Bus. Development
Mark Sorenson
VP - R & D
Bryce Timm
Browse more venture capital transactions:
Prev: 7/29/2026: Pangram venture capital transaction
Next: 7/29/2026: LearnVector venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs